Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q1 2018 · 10-Q
Revenue$56.16M$56.16M±0.0% vs Q1 2017 Net Income$45.28M$45.28M±0.0% vs Q1 2017 EPS Diluted$1.83$1.83±0.0% vs Q1 2017 Operating Income$37,041,000+262.6% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Margins · derivedOperating margin66.0%+47.8 pt vs Q1 2017
Net margin80.6%±0.0 pt vs Q1 2017
ended Mar 31, 2018 · filed May 9, 2018 · 39 d after period end